Novartis has received nod from the US health regulator for its heart failure treatment tablets - LCZ696 - and the company plans to launch the medicine in India. It will benefit many patients afflicted with heart failure.
The company plans to launch LCZ696 (sacubitril/valsartan) tablets under the brand name 'Entresto' in the US market. The tablets-LCZ696 will reduce risk of death from cardiovascular causes by 20 percent and will offer to patients a much greater opportunity to live longer and stay out of hospital.
Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
| Company Name | CMP |
|---|---|
| Redington | 222.80 |
| Adani Enterprises | 2505.65 |
| Amrapali Industries | 18.21 |
| Rashi Peripheral | 530.50 |
| PDS | 300.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: